New Research Points to Ways to Shield Beta Cells From Damage

New findings presented at the American Diabetes Association (ADA) Scientific Sessions suggest that 2 distinct molecular pathways could offer new ways to protect insulin-producing β cells from the damage that drives diabetes.^1,2

The studies describe separate mechanisms that either shield β cells from immune-mediated destruction or restore their function once stressed. Together, the studies point toward a broader strategy: rather than only managing insulin levels after β cell loss has occurred, researchers are working to intervene earlier, preserving the cells responsible for producing insulin in the first place.

SMOC1 is a basement membrane protein that modulates growth factor signaling and cell differentiation, with established roles in ocular and limb development. In adult human islets affected by T2D, SMOC1 misexpression has been linked to reduced insulin expression and β-cell dysfunction.³ Whether it also contributes to normal endocrine development had not previously been established.

Protecting Beta Cells From Immune Attack

The first poster focused on a long noncoding RNA called SNHG6 and its role in protecting human β cells from cytokine-induced, immune-mediated damage.¹ Inflammatory cytokines are known to trigger β cell death and dysfunction, in part by making cells more visible and vulnerable to immune attack.

The researchers found that increasing SNHG6 activity reduced β cell death under inflammatory stress, helped cells maintain their identity and function, and lowered the immunogenic signals associated with immune targeting.

Reversing Dysfunction in Type 2 Diabetes

The second presentation examined a different target: phosphodiesterase-4B (PDE4B), an enzyme implicated in β cell dysfunction associated with type 2 diabetes.² The researchers found that elevated PDE4B levels constrained cyclic AMP, a signaling molecule important for insulin secretion, and were linked to impaired insulin release and a loss of β cell identity.

Notably, reducing PDE4B activity helped restore β cell function and reduced markers of cellular stress, suggesting the enzyme may be a viable therapeutic target for reversing and not just slowing β cell decline.

A Shared Strategy Across Diabetes Research

Although the 2 studies address different disease mechanisms—immune-mediated β cell destruction vs metabolic and secretory dysfunction in type 2 diabetes—both point to the same underlying principle: β cell preservation may be achievable through targeted molecular intervention rather than solely through downstream insulin replacement.^1,2 This dual focus reflects a broader trend in diabetes research toward disease-modifying approaches that address root causes of β cell loss.

Therapies aimed at β cell preservation could eventually shift the economics of diabetes care by delaying or reducing dependence on exogenous insulin and other downstream interventions. Although the findings remain in early stages, managed care organizations may want to monitor this research area closely, as β cell–preserving therapies could represent a new treatment class distinct from current glucose-lowering or immunomodulatory agents. Should these targets progress into clinical development, formulary and coverage strategies may need to account for their potential to alter long-term disease trajectories rather than simply manage symptoms.

For payers tracking the diabetes cell therapy and biologics pipeline, this research signals that both stem cell–derived islet products and β-cell–preserving molecular therapies remain in early discovery. Genes such as SMOC1, SNHG6, and PDE4B could eventually support disease-modifying drug classes distinct from current glucose-lowering or immunomodulatory agents, potentially reducing long-term costs tied to insulin dependence or graft failure.

References

1. Lu G, Kang RB, Aldaco J, et al. Long noncoding RNA SNHG6 reduces cytokine-induced human β-cell immunogenicity and death. Diabetes. https://doi.org/10.2337/db26-1271-OR
2. Lu G, Kang RB, Aldaco J, et al. Phosphodiesterase-4B constrains cyclic AMP levels and drives human β-cell dysfunction in type 2 diabetes. Diabetes. https://doi.org/10.2337/db26-1204-OR
3. Kang, RB, Varela M, Oh E, et al. Human pancreatic α-cell heterogeneity and trajectory inference analyses reveal SMOC1 as a β-cell dedifferentiation gene. Nat Commun. https://doi.org/10.1038/s41467-025-62670-5